Lower-dose immune therapy plus hetrombopag for older adults with severe aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe or very severe aplastic anemia.
- You are 65 years or older.
- You can complete all screening tests and swallow tablets.
- You have not been treated with ATG or high-dose cyclophosphamide before.
- You have not used cyclosporine or tacrolimus for more than 12 months, or TPO-RA (like eltrombopag) for more than 3 months.
- You do not have uncontrolled cancer or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
This trial tests a new way of preparing adult patients with hard-to-treat aplastic anemia for a stem cell transplant. It uses a lower-intensity conditioning regimen (TMI) and umbilical cord blood, which may be safer and more effective for patients who have failed other treatments.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests a gentler conditioning regimen (using lower-dose radiation) before a stem cell transplant for people aged 50 and older with aplastic anemia. The goal is to make the transplant safer and more tolerable for older patients.
This trial compares two standard treatments for severe aplastic anemia (a condition where the bone marrow stops making enough blood cells). One treatment is a stem cell transplant from a donor, and the other is a drug therapy that suppresses the immune system. The goal is to see which works better as a first treatment.
Hear when a new Elderly (People Aged 65 or More) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.